NVAX
Price
$7.06
Change
-$0.41 (-5.49%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
1.14B
12 days until earnings call
WXIBF
Price
$2.74
Change
+$0.32 (+13.22%)
Updated
Apr 14 closing price
Capitalization
11.93B
Ad is loading...

NVAX vs WXIBF

Header iconNVAX vs WXIBF Comparison
Open Charts NVAX vs WXIBFBanner chart's image
Novavax
Price$7.06
Change-$0.41 (-5.49%)
Volume$72.61K
Capitalization1.14B
Wuxi Biologics Cayman
Price$2.74
Change+$0.32 (+13.22%)
Volume$5.4K
Capitalization11.93B
NVAX vs WXIBF Comparison Chart
Loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVAX vs. WXIBF commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a Buy and WXIBF is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (NVAX: $7.07 vs. WXIBF: $2.74)
Brand notoriety: NVAX: Notable vs. WXIBF: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 116% vs. WXIBF: 195%
Market capitalization -- NVAX: $1.14B vs. WXIBF: $11.93B
NVAX [@Biotechnology] is valued at $1.14B. WXIBF’s [@Biotechnology] market capitalization is $11.93B. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 0 FA rating(s) are green whileWXIBF’s FA Score has 2 green FA rating(s).

  • NVAX’s FA Score: 0 green, 5 red.
  • WXIBF’s FA Score: 2 green, 3 red.
According to our system of comparison, WXIBF is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 6 TA indicator(s) are bullish.

  • NVAX’s TA Score: 6 bullish, 3 bearish.

Price Growth

NVAX (@Biotechnology) experienced а +17.83% price change this week, while WXIBF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

NVAX is expected to report earnings on Aug 06, 2025.

WXIBF is expected to report earnings on Mar 25, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
WXIBF($11.9B) has a higher market cap than NVAX($1.14B). WXIBF YTD gains are higher at: 26.267 vs. NVAX (-12.065). WXIBF has higher annual earnings (EBITDA): 5.5B vs. NVAX (-108.04M). WXIBF has higher revenues than NVAX: WXIBF (17B) vs NVAX (682M).
NVAXWXIBFNVAX / WXIBF
Capitalization1.14B11.9B10%
EBITDA-108.04M5.5B-2%
Gain YTD-12.06526.267-46%
P/E RatioN/A25.69-
Revenue682M17B4%
Total Cash923MN/A-
Total Debt230MN/A-
FUNDAMENTALS RATINGS
NVAX vs WXIBF: Fundamental Ratings
NVAX
WXIBF
OUTLOOK RATING
1..100
1699
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10016
PRICE GROWTH RATING
1..100
6348
P/E GROWTH RATING
1..100
10011
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WXIBF's Valuation (70) in the null industry is in the same range as NVAX (87) in the Biotechnology industry. This means that WXIBF’s stock grew similarly to NVAX’s over the last 12 months.

WXIBF's Profit vs Risk Rating (100) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that WXIBF’s stock grew similarly to NVAX’s over the last 12 months.

WXIBF's SMR Rating (16) in the null industry is significantly better than the same rating for NVAX (100) in the Biotechnology industry. This means that WXIBF’s stock grew significantly faster than NVAX’s over the last 12 months.

WXIBF's Price Growth Rating (48) in the null industry is in the same range as NVAX (63) in the Biotechnology industry. This means that WXIBF’s stock grew similarly to NVAX’s over the last 12 months.

WXIBF's P/E Growth Rating (11) in the null industry is significantly better than the same rating for NVAX (100) in the Biotechnology industry. This means that WXIBF’s stock grew significantly faster than NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAX
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCIHX16.630.22
+1.34%
NYLI PineStone International Equity Cl P
NAWCX43.75N/A
N/A
Voya Global High Dividend Low Vol C
OGIYX44.97N/A
N/A
Invesco Global Opportunities Y
MVCKX29.23N/A
N/A
MFS Mid Cap Value R6
CAPOX10.71N/A
N/A
Absolute Capital Opportunities Instl

WXIBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, WXIBF has been loosely correlated with WXXWY. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if WXIBF jumps, then WXXWY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WXIBF
1D Price
Change %
WXIBF100%
N/A
WXXWY - WXIBF
46%
Loosely correlated
+2.03%
JAGX - WXIBF
22%
Poorly correlated
+20.84%
NVAX - WXIBF
21%
Poorly correlated
-5.35%
ELVAF - WXIBF
21%
Poorly correlated
N/A
EVAX - WXIBF
20%
Poorly correlated
+6.71%
More